Company intelligence / Profile preview
TheraVida, Inc.
Chapel Hill, North Carolina, United Statestheravida.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The lead candidate Anhydrix™ has successfully completed a Phase 2 human study for the treatment of primary focal hyperhidrosis. Initial clinical trials have shown maintenance of therapeutic effect with improved patient tolerability compared to existing therapies. This suggests potential for better long-term compliance and outcomes.
- Therapeutic areas
- Men's HealthEndocrinologyDermatologyUrology
- Modalities
- Small molecules (combination drug technology involving agonists and antagonists)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on TheraVida, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraVida, Inc..